NYSE Arca · PTHS
Pelthos Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PTHS: Nov 12, 2026
Pelthos Therapeutics Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.83. The reported EPS for the same quarter last year was $-5.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.83 | $-1.60 | $-4.60 | 4 |
| Dec 2026 | $-2.54 | $-1.10 | $-4.71 | 4 |
| Mar 2027 | $-0.56 | $-0.23 | $-0.89 | 2 |
| Jun 2027 | $0.31 | $0.98 | $-0.37 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Zacks · BNK Invest · Fintel- The Motley Fool · Aug 20, 9:04 AM EDTPelthos (PTHS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 13, 8:25 AM EDTPelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue EstimatesPelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- BNK Invest · Jun 16, 4:20 PM EDTTuesday 6/16 Insider Buying Report: LODE, PTHSBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- Zacks · May 14, 8:20 AM EDTPelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue EstimatesPelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +22.75% and +12.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Apr 2, 8:04 PM EDTCantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight RecommendationFintel reports that on April 1, 2026, Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation. Analyst Price Forecast Suggests 191.67% Upside
- Zacks · Mar 19, 7:40 AM EDTPelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue EstimatesPelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Feb 27, 6:02 AM ESTPiper Sandler Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight RecommendationFintel reports that on February 27, 2026, Piper Sandler initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation. Analyst Price Forecast Suggests ∞% Upside
- Fintel · Dec 3, 7:05 PM ESTLake Street Initiates Coverage of Pelthos Therapeutics (PTHS) with Buy RecommendationFintel reports that on December 3, 2025, Lake Street initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Buy recommendation. Analyst Price Forecast Suggests 167.78% Upside
- Fintel · Dec 3, 9:23 AM ESTHC Wainwright & Co. Initiates Coverage of Pelthos Therapeutics (PTHS) with Buy RecommendationFintel reports that on December 3, 2025, HC Wainwright & Co. initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Buy recommendation. Analyst Price Forecast Suggests 167.78% Upside
- Fintel · Nov 25, 7:05 PM ESTRoth Capital Initiates Coverage of Pelthos Therapeutics (PTHS) with Buy RecommendationFintel reports that on November 25, 2025, Roth Capital initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Buy recommendation. Analyst Price Forecast Suggests 144.53% Upside
- Fintel · Nov 16, 11:19 PM ESTPelthos Therapeutics (PTHS) Price Target Increased by 20.00% to 67.32The average one-year price target for Pelthos Therapeutics (NYSEAM:PTHS) has been revised to $67.32 / share. This is an increase of 20.00% from the prior estimate of $56.10 dated November 7, 2025. The price target is an average of many targets provided by anal
- Fintel · Nov 14, 7:05 PM ESTOppenheimer Reiterates Pelthos Therapeutics (PTHS) Outperform RecommendationFintel reports that on November 14, 2025, Oppenheimer reiterated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Outperform recommendation. Analyst Price Forecast Suggests 60.98% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Pelthos Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.